Compare TNXP & FUNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TNXP | FUNC |
|---|---|---|
| Founded | 2007 | 1900 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.6M | 232.8M |
| IPO Year | 2008 | 2012 |
| Metric | TNXP | FUNC |
|---|---|---|
| Price | $14.09 | $37.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 366.4K | 7.3K |
| Earning Date | 05-11-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 2.80% |
| EPS Growth | ★ 91.75 | 19.68 |
| EPS | N/A | ★ 1.03 |
| Revenue | $13,107,000.00 | ★ $18,426,000.00 |
| Revenue This Year | $558.11 | $13.05 |
| Revenue Next Year | $38.29 | $6.56 |
| P/E Ratio | ★ N/A | $36.29 |
| Revenue Growth | ★ 29.85 | 4.01 |
| 52 Week Low | $11.60 | $28.00 |
| 52 Week High | $69.65 | $41.95 |
| Indicator | TNXP | FUNC |
|---|---|---|
| Relative Strength Index (RSI) | 51.94 | 49.38 |
| Support Level | $12.43 | $37.22 |
| Resistance Level | $14.85 | $37.68 |
| Average True Range (ATR) | 1.16 | 0.71 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 49.70 | 36.07 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.